Brought to you by 
Schering-Plough and Alder collaborate on antibody production; assumed terminated
03 Apr 2014
Executive Summary
Antibody therapeutics company Alder Biopharmaceuticals Inc. entered a deal with Schering-Plough to jointly identify and produce up to ten antibodies using its proprietary selection and production technologies. This is Alder's first partnership with a large pharmaceutical company.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Synthesis Technologies, Production Processes
-
Large Molecule
- Antibodies
Deal Status
- Terminated
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Schering-Plough and Alder collaborate on antibody production; assumed terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice